D. E. Shaw & Co., Inc. - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q3 2022$201,000
-67.6%
34,578
-66.7%
0.00%
-100.0%
Q2 2022$620,000
+4033.3%
103,839
+686.2%
0.00%
Q2 2020$15,000
-16.7%
13,207
-38.3%
0.00%
Q3 2019$18,000
+80.0%
21,396
+89.3%
0.00%
Q2 2019$10,000
-9.1%
11,3020.0%0.00%
Q1 2019$11,000
+37.5%
11,3020.0%0.00%
Q4 2018$8,000
-66.7%
11,3020.0%0.00%
Q3 2018$24,00011,3020.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 6,535,674$27,449,8319.21%
Bleichroeder LP 3,893,730$16,353,6663.49%
AIGH Capital Management LLC 2,100,000$8,820,0003.25%
Ally Bridge Group (NY) LLC 550,000$2,310,0003.03%
Ghost Tree Capital, LLC 2,000,000$8,400,0002.48%
Bain Capital Life Sciences Investors, LLC 4,702,996$19,7532.47%
Altium Capital Management LP 850,000$3,570,0001.98%
Parkman Healthcare Partners LLC 1,753,630$7,365,2461.60%
BVF INC/IL 8,813,021$37,014,6881.35%
Sio Capital Management, LLC 526,239$2,210,2041.09%
View complete list of CTI BIOPHARMA CORP shareholders